版本:
中国

BRIEF-Trial data demonstrate robust response rate with Indoximod in combination with Keytruda

April 4 Newlink Genetics Corp

* Interim phase 2 data demonstrate robust response rate with Indoximod in combination with Keytruda for patients with advanced melanoma at AACR plenary

* Combination was generally well tolerated with low rates of grade 3 or higher adverse events

* Data report on cohort of 60 evaluable patients who received combination of Indoximod plus Pembrolizumab which demonstrated 52 pct ORR, 73 pct DCR

* Expect further clinical validation of IDO pathway as an immuno-oncology target throughout 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐